You are here: Industry Insights > Prostate Cancer

News List

Clean interim safety review of RhoVac's clinical phase IIb study in prostate cancer prnasia
July 12, 2021
RhoVac AB, a Swedish cancer immunotherapy company, announces on July 9th 2021, that its Safety Monitoring Committee has conducted a planned interim safety review of its clinical phase IIb trial in prostate cancer, known as BRaVac.
Study finds drugs used to treat prostate cancer could help treat COVID-19 expresspharma
July 02, 2021
Research showed that treatment with the androgen-blocking drug enzalutamide reduced TMPRSS2 levels in lab cultures of human lung cells. It significantly reduced SARS-CoV-2 entry and infection in lung cells.
Novartis prostate cancer drug gets FDA breakthrough designation pharmaceutical-technology
June 18, 2021
The FDA breakthrough designation is based on positive results from the Phase III VISION study of ¹⁷⁷Lu-PSMA-617.
Erleada® improves survival without damaging quality of life in prostate cancer trial europeanpharmaceuticalreview
May 31, 2021
Data shows metastatic castration-sensitive prostate cancer patients treated with Erleada® (apalutamide) were 35 percent less likely to die and had maintained quality of life.
FDA Approves Pylarify (piflufolastat F 18) PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer drugs
May 31, 2021
FDA has approved Pylarify (piflufolastat F 18) – a drug for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer.
BDR Pharma launches generic Rucaparib to treat advanced ovarian and prostate cancers expresspharma
May 31, 2021
BDR Pharmaceutical launched BDPARIB (Rucaparib) to treat advanced ovarian and prostate cancers.
FDA Approves Tracer That Improves Detection of Advanced Prostate Cancer drugs
May 31, 2021
A new imaging agent that detects prostate cancer that has spread to other parts of the body has been approved by the U.S. Food and Drug Administration.
Janssen’s Erleada maintains quality of life for prostate cancer patients pharmatimes
May 27, 2021
Janssen’s Erleada in addition to androgen deprivation therapy (ADT) maintained prostate cancer patients’ health-related quality of life (HRQoL), according to new patient-reported outcomes (PRO) data.
NICE turns down Janssen's Erleada pharmatimes
May 21, 2021
The National Institute for Health and Care Excellence (NICE) has published draft guidance rejecting Janssen's Erleada (apalutamide) with androgen deprivation therapy (ADT) for treating prostate cancer.
Astellas’ Xtandi bags additional MHRA approval in prostate cancer pharmatimes
May 13, 2021
Japanese pharma company Astellas has announced that its prostate cancer therapy Xtandi has gained an approval for an additional indication from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA).

Previous page 1 2 3 4 5 6 7 8 9 10 Next page